Generic Name and Formulations:
Lofexidine (as HCl) 0.18mg; tabs.
US WorldMeds, LLC
RECENT UPDATESMonograph added.
Indications for LUCEMYRA:
Mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Initially 3 tabs 4 times daily (5–6hrs between doses) during peak withdrawal symptoms for up to 14 days; max single dose: 0.72mg (4 tabs); max daily dose: 2.88mg (16 tabs). Discontinue gradually over 2–4 days (eg, reduce by 1 tab/dose every 1–2 days). Hepatic impairment (moderate): 2 tabs 4 times daily; (severe): 1 tab 4 times daily. Renal impairment (mild or moderate): 2 tabs 4 times daily; (severe, ESRD, or on dialysis): 1 tab 4 times daily.
Risk of hypotension, bradycardia, syncope. Monitor vital signs before dosing and for symptoms of bradycardia and orthostasis. Avoid in severe coronary insufficiency, recent MI, cerebrovascular disease, chronic renal failure, marked bradycardia, concomitant pulse or BP-lowering medications, congenital long QT syndrome. Correct electrolyte abnormalities prior to initiation. CHF, bradyarrhythmias, hepatic/renal impairment, concomitant QT-prolonging drugs (eg, methadone): monitor ECG. Increased risk of opioid overdose after opioid discontinuation. Use only in conjunction with comprehensive management program for treatment of opioid use disorder. Avoid abrupt cessation. Known CYP2D6 poor metabolizers: monitor. Hepatic or renal impairment: see Adult. Elderly (>65yrs): consider dose adjustment. Pregnancy. Nursing mothers.
Central alpha-2 agonist.
Increased QT prolongation with concomitant methadone; monitor ECG. May antagonize oral naltrexone when concomitant within 2hrs of Lucemyra. Potentiates CNS depressant effects of benzodiazepines. May potentiate alcohol, barbiturates, other sedatives. Potentiated by CYP2D6 inhibitors (eg, paroxetine); monitor for orthostatic hypotension, bradycardia.
Orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, dry mouth; discontinuation symptoms (eg, diarrhea, insomnia, anxiety, chills, hyperhidrosis, extremity pain).
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Age of Onset of Bipolar Disorder Linked With Substance Use Disorders
- Rapid Cycling in Bipolar Disorder: Overview and Expert Perspectives
- Low Testosterone Linked With Social Anxiety in Boys With Klinefelter Syndrome
- Posttraumatic Stress Disorder Associated With Reduced Brain Volume
- First-Episode Drug-Naive Patients With Schizophrenia More Likely to Attempt Suicide
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Healthcare Community Should Favor More Restrictive Alcohol Policies
- How to Respond to a Patient's Request for Prayer: A Clinician's Dilemma
- Major Barriers to Useful Risk Prediction Must Be Overcome to Reach the Full Potential of Big Data
- ACA Coverage Gains Include Workers Without Insurance
- Steps Provided for Discharging Patients From Practice